Skip to main content

Advertisement

Table 2 Treatment schedule and number of mice for each group

From: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

Group Treatment Number of mice
177Lu-TATE TMZ
Control Placebo 5
1: PRRT single 30 MBq day 0 Placebo 8
2: PRRT double 30 MBq day 0 Placebo 8
3: TMZ 50 mg/kg for 14 days from day 0 8
4: PRRT + TMZ at day 14 30 MBq day 0 50 mg/kg for 14 days from day 14 8
5: PRRT + TMZ 30 MBq day 0 50 mg/kg for 14 days from day 0 8
6: TMZ + PRRT at day 14 30 MBq day 14 50 mg/kg for 14 days from day 0 10
  1. 177 Lu-TATE lutetium-177-labelled octreotate, TMZ temozolomide, PRRT peptide receptor radionuclide therapy